Segall Bryant & Hamill’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.9M | Sell |
1,086,396
-46,630
| -4% | -$450K | 0.19% | 192 |
|
|
2026
Q1 | $8.41M | Sell |
1,133,026
-599,003
| -35% | -$6.3M | 0.12% | 247 |
|
|
2025
Q4 | $20.4M | Sell |
1,732,029
-83,920
| -5% | -$905K | 0.28% | 125 |
|
|
2025
Q3 | $14M | Sell |
1,815,949
-546,100
| -23% | -$3.83M | 0.19% | 183 |
|
|
2025
Q2 | $17.3M | Buy |
2,362,049
+11,303
| +0.5% | +$91.2K | 0.24% | 141 |
|
|
2025
Q1 | $22.3M | Buy |
2,350,746
+236,924
| +11% | +$2.96M | 0.34% | 93 |
|
|
2024
Q4 | $34.8M | Buy |
2,113,822
+220,415
| +12% | +$3.42M | 0.48% | 53 |
|
|
2024
Q3 | $27.9M | Buy |
1,893,407
+759,524
| +67% | +$11.9M | 0.38% | 81 |
|
|
2024
Q2 | $15.7M | Sell |
1,133,883
-198,098
| -15% | -$2.81M | 0.28% | 117 |
|
|
2024
Q1 | $20.9M | Sell |
1,331,981
-25,456
| -2% | -$393K | 0.39% | 89 |
|
|
2023
Q4 | $22M | Sell |
1,357,437
-2,186
| -0.2% | -$35.8K | 0.42% | 74 |
|
|
2023
Q3 | $16.7M | Buy |
1,359,623
+18,549
| +1% | +$276K | 0.19% | 139 |
|
|
2023
Q2 | $21.6M | Buy |
1,341,074
+220,018
| +20% | +$3.63M | 0.23% | 123 |
|
|
2023
Q1 | $19.5M | Buy |
1,121,056
+52,343
| +5% | +$746K | 0.21% | 134 |
|
|
2022
Q4 | $9.87M | Sell |
1,068,713
-43,161
| -4% | -$402K | 0.11% | 221 |
|
|
2022
Q3 | $9.58M | Buy |
+1,111,874
| New | +$11M | 0.11% | 212 |
|
|
2021
Q4 | – | Sell |
-39,654
| Closed | -$1.91M | – | 690 |
|
|
2021
Q3 | $1.91M | Sell |
39,654
-40,345
| -50% | -$1.87M | 0.02% | 466 |
|
|
2021
Q2 | $3.61M | Sell |
79,999
-27,821
| -26% | -$1.23M | 0.04% | 384 |
|
|
2021
Q1 | $5.2M | Sell |
107,820
-5,078
| -4% | -$264K | 0.05% | 328 |
|
|
2020
Q4 | $6.08M | Sell |
112,898
-10,327
| -8% | -$467K | 0.07% | 260 |
|
|
2020
Q3 | $4.55M | Buy |
123,225
+2,639
| +2% | +$98.1K | 0.06% | 274 |
|
|
2020
Q2 | $3.73M | Sell |
120,586
-12,134
| -9% | -$336K | 0.06% | 261 |
|
|
2020
Q1 | $3.66M | Buy |
132,720
+7,924
| +6% | +$237K | 0.07% | 243 |
|
|
2019
Q4 | $3.65M | Sell |
124,796
-87,706
| -41% | -$2.09M | 0.06% | 297 |
|
|
2019
Q3 | $4.07M | Sell |
212,502
-2,078
| -1% | -$48.7K | 0.06% | 304 |
|
|
2019
Q2 | $4.71M | Sell |
214,580
-18,009
| -8% | -$395K | 0.07% | 286 |
|
|
2019
Q1 | $4.76M | Sell |
232,589
-36,381
| -14% | -$632K | 0.07% | 276 |
|
|
2018
Q4 | $3.39M | Sell |
268,970
-23,420
| -8% | -$349K | 0.06% | 315 |
|
|
2018
Q3 | $4.49M | Sell |
292,390
-60,274
| -17% | -$833K | 0.07% | 309 |
|
|
2018
Q2 | $4.62M | Sell |
352,664
-88,716
| -20% | -$976K | 0.07% | 305 |
|
|
2018
Q1 | $3.6M | Buy |
441,380
+6,952
| +2% | +$56.3K | 0.08% | 247 |
|
|
2017
Q4 | $3.85M | Buy |
434,428
+60,360
| +16% | +$557K | 0.08% | 233 |
|
|
2017
Q3 | $4.16M | Buy |
374,068
+284,572
| +318% | +$2.77M | 0.1% | 221 |
|
|
2017
Q2 | $802K | Buy |
+89,496
| New | +$710K | 0.02% | 382 |
|
Other funds holding NEO
FLAM
GF
NAMI
B
Segall Bryant & Hamill's NEO Position: Q2 2026 in Review
Segall Bryant & Hamill reduced its NeoGenomics (NEO) stake by 4.1% in Q2 2026, selling an estimated $450K and leaving 1,086,396 shares worth $15.9M. The position accounts for 0.19% of the portfolio, ranked #192.
Segall Bryant & Hamill first reported a position in NEO in Q2 2017 and has held it in 34 quarters since. The position peaked at $34.8M in Q4 2024. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.
- Segall Bryant & Hamill held 1,086,396 shares of NeoGenomics worth $15.9M as of Q2 2026.
- Segall Bryant & Hamill sold 46,630 NeoGenomics shares in Q2 2026, an estimated $450K.
- NeoGenomics made up 0.19% of Segall Bryant & Hamill's portfolio in Q2 2026, its #192 holding.
- Segall Bryant & Hamill first reported a position in NeoGenomics in Q2 2017 and has held it in 34 quarters since.
- Segall Bryant & Hamill's NeoGenomics position peaked at $34.8M in Q4 2024.
- 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.
Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.